{"created":"2023-05-15T14:37:39.146674+00:00","id":48574,"links":{},"metadata":{"_buckets":{"deposit":"30e535ba-dd2c-4e61-9474-9058e59d8981"},"_deposit":{"created_by":1,"id":"48574","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"48574"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00048574","sets":["1"]},"author_link":["488424","488417","488413","488407","488409","488427","488423","488418","488421","488416","488431","488425","488411","488408","488420","488414","488415","488429","488426","488430","488410","488419","488422","488412","488428","488432"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017-06","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"20","bibliographicPageEnd":"3965","bibliographicPageStart":"3955","bibliographicVolumeNumber":"123","bibliographic_titles":[{"bibliographic_title":"Cancer"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"BACKGROUND: \n\\nThe objective of this study was to evaluate the safety and efficacy of carbon-ion radiotherapy (CIRT) in patients with hepatocellular carcinoma (HCC) with stepwise dose escalation and hypofractionation in 2 combined prospective trials.\n\\nMETHODS: \n\\nSequential phase 1/2 (protocol 9603) and phase 2 (protocol 0004) trials were conducted for patients with histologically proven HCC. The phase 1 component of protocol 9603 was a dose-escalation study; CIRT was delivered in 12, 8, or 4 fractions. After determination of the recommended dose, 2 phase 2 trials were performed in an expanded cohort, and the data were pooled to analyze toxicity, local control, and overall survival.\n\\nRESULTS: \n\\nIn the phase 1 component of protocol 9603, 69.6, 58.0, and 52.8 Gy (relative biological effectiveness [RBE]) in 12, 8, and 4 fractions, respectively, constituted the maximum tolerated doses, and 52.8 Gy (RBE) in 4 fractions was established as the recommended dose regimen for the 2 phase 2 studies. In 124 patients with a total of 133 lesions, few severe adverse effects occurred, and local-control and overall survival rates at 1, 3, and 5 years were 94.7% and 90.3%, 91.4% and 50.0%, and 90.0% and 25.0%, respectively; this included 1-, 3-, and 5-year local-control rates of 97.8%, 95.5%, and 91.6%, respectively, in the phase 2 study. In a multivariate analysis, Child-Pugh class B and the presence of a tumor thrombus were significant factors for mortality.\n\\nCONCLUSIONS: \n\\nThe safety and efficacy of CIRT in 12, 8, and 4 fractions were confirmed, with 52.8 Gy (RBE) in 4 fractions established as the recommended treatment course for eligible HCC patients. Cancer 2017. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.","subitem_description_type":"Abstract"}]},"item_8_relation_13":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"28662297","subitem_relation_type_select":"PMID"}}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1002/cncr.30816 ","subitem_relation_type_select":"DOI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0008-543X","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kasuya, Goro"}],"nameIdentifiers":[{"nameIdentifier":"488407","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Katou, Hirotoshi"}],"nameIdentifiers":[{"nameIdentifier":"488408","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yasuda, Shigeo"}],"nameIdentifiers":[{"nameIdentifier":"488409","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Hiroshi"}],"nameIdentifiers":[{"nameIdentifier":"488410","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yamada, Shigeru"}],"nameIdentifiers":[{"nameIdentifier":"488411","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Haruyama, Yasuo"}],"nameIdentifiers":[{"nameIdentifier":"488412","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kobashi, Gen"}],"nameIdentifiers":[{"nameIdentifier":"488413","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ebner, Daniel"}],"nameIdentifiers":[{"nameIdentifier":"488414","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Okada, Naomi"}],"nameIdentifiers":[{"nameIdentifier":"488415","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Makishima, Hirokazu"}],"nameIdentifiers":[{"nameIdentifier":"488416","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Miyazaki, Masaru"}],"nameIdentifiers":[{"nameIdentifier":"488417","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kamada, Tadashi"}],"nameIdentifiers":[{"nameIdentifier":"488418","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsujii, Hirohiko"}],"nameIdentifiers":[{"nameIdentifier":"488419","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"粕谷 吾朗","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"488420","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"加藤 博敏","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"488421","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"安田 茂雄","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"488422","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻 比呂志","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"488423","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"山田 滋","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"488424","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"春山 康夫","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"488425","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"小橋 元","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"488426","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"エブナー ダニエル","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"488427","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"岡田 直美","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"488428","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"牧島 弘和","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"488429","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"宮崎 勝","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"488430","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鎌田 正","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"488431","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻井 博彦","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"488432","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-03-14"},"publish_date":"2018-03-14","publish_status":"0","recid":"48574","relation_version_is_last":true,"title":["Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T23:26:39.902198+00:00"}